TIFFANY MOOS: Open Payments
NPI 1427783380 · HALSTEAD, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$490 in 18 payments from 12 companies in 2025. Trend: 2023 $838 · 2024 $798 · 2025 $490
Food & beverage: $490
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 2 | $157 |
| Otsuka America Pharmaceutical, Inc. | 4 | $91 |
| Merck Sharp & Dohme LLC | 3 | $59 |
| Gilead Sciences, Inc. | 1 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $27 |
| Astellas Pharma US Inc | 1 | $21 |
| Organon LLC | 1 | $21 |
| Antares Pharma, Inc. | 1 | $20 |
| ABBVIE INC. | 1 | $20 |
| Novo Nordisk Inc | 1 | $17 |
Products named: SPRAVATO, REXULTI, PIFELTRO, CAPLYTA, Veozah, NEXPLANON, XYOSTED, QULIPTA.
Industry payments across KS — which companies pay providers there.
